This result suggests that without considering the adverse reactions, IO + Anti‐angio + Chemo may be a wise choice to improve OS, PFS, and ORR of first‐line treatment for PD‐L1‐high advanced NSCLC patients. Here, CD274 is linked to non-small cell lung carcinoma.